YD Bio (YDES) Prepaid Assets (2024 - 2025)

YD Bio's (YDES) quarterly Prepaid Assets came in at $1324.0 billion in Q4 2025, up 579.89% year-on-year from $194.7 billion in Q4 2024, and up 342358213.47% on a QoQ basis from $386734.0 in Q2 2025.

YD Bio (YDES) Prepaid Assets (2024 - 2025) Analysis & Trends

YD Bio (YDES) has 2 years of Prepaid Assets data on file, last reported at $1324.0 billion in Q4 2025.

  • On a quarterly basis, Prepaid Assets rose 579.89% year-over-year to $1324.0 billion in Q4 2025; TTM through Dec 2025 was $1324.0 billion, a 579.89% increase from a year earlier, with the FY2025 full-year figure at $1324.0 billion, up 579.89% from the prior year.
  • Prepaid Assets for Q4 2025 stood at $1324.0 billion, up from $386734.0 in the prior quarter.
  • Over the last five years, Prepaid Assets for YDES reached as high as $1324.0 billion in Q4 2025 and fell as low as $386734.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 YD Bio 157.46 Mn 151.45 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 1,324.02 Bn
Jun 30, 2025 386,734.00
Dec 31, 2024 194.74 Bn